Last €2.28 EUR
Change Today +0.024 / 1.06%
Volume 0.0
B8F On Other Exchanges
As of 2:12 AM 12/22/14 All times are local (Market data is delayed by at least 15 minutes).

biofrontera ag (B8F) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/19/14 - €4.15
52 Week Low
09/17/14 - €2.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIOFRONTERA AG (B8F)

Related News

No related news articles were found.

biofrontera ag (B8F) Related Businessweek News

No Related Businessweek News Found

biofrontera ag (B8F) Details

Biofrontera AG, a biopharmaceutical company, is engaged in the discovery, development, and distribution of dermatological drugs and dermatological-tested cosmetics for the treatment and care of diseased skin. Its products include Ameluz, a prescription drug for the treatment of actinic keratosis, a superficial skin cancer; BF-RhodoLED, a lamp for photodynamic therapy; and Belixos, a cream with herbal ingredients for the care of inflamed, itchy, and flaky skin, such as localized itching, insect bites, burns, nuerodermatitis, and psoriasis. The company is also developing BF-derm1, which is in Phase II clinical trial for the treatment of chronic and antihistamine-refractory urticaria; and BF-1, a specific serotonin receptor antagonist that is in Phase I clinical trial for migraine prophylaxis. In addition, it focuses on developing Ameluz for other superficial cancer and warts. The company was founded in 1997 and is headquartered in Leverkusen, Germany.

41 Employees
Last Reported Date: 11/13/14
Founded in 1997

biofrontera ag (B8F) Top Compensated Officers

Co-Founder, Chairman of Management Board and ...
Total Annual Compensation: €412.0K
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €100.0K
Compensation as of Fiscal Year 2013.

biofrontera ag (B8F) Key Developments

Biofrontera Launches Third Product of its Derma-Cosmetic Line Belixos

Biofrontera has launched the third product of its derma-cosmetic line Belixos®, a cooling and cleaning day care gel designed for situations of increased sebum production. Belixos® Gel was developed for the special needs of inflamed, reddened skin prone to impurities, the ideal basic care for rosacea and acne. To minimize the risk for sensitive reactions and skin irritations the gel formulation was reduced to just a few high-value ingredients. The formulation causes a cooling sensation and combines the extracts of cinnamon bark in the Sepicontrol A5 complex and mahonia aquifolium with Biofrontera's innovative Biocolloid technology. The extract of mahonia relieves inflammation, redness and itching, typical signs of rosacea. The active ingredient complex Sepicontrol A5 with cinnamon bark has antibacterial activity and removes callused skin, regulates sebum and clears congested sebaceous glands. As with the other products in the Belixos®  dermo-cosmetic series in cream and liquid formulations, the underlying biocolloid technology causes an optimized penetration of this unique ingredient combination from traditional medicinal plants extracts.

Biofrontera AG Presents at 4th Annual Berenberg 1 - 1 Symposium @ German Equity Forum, Nov-26-2014

Biofrontera AG Presents at 4th Annual Berenberg 1 - 1 Symposium @ German Equity Forum, Nov-26-2014 . Venue: Maritim Hotel, Theodor-Heuss-Allee 3, 60486 Frankfurt am Main, Germany.

Biofrontera Announces Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Biofrontera announced earnings results for the third quarter ended September 30, 2014. In the third quarter of the 2014, the company achieved a significant increase in revenue of 61% compared to the same period of the previous year. For nine months, the company reported revenue of EUR 1,992,000, 7% higher overall than in the period for the previous year. The loss before tax was EUR 7,955,000 against EUR 6,022,000 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
B8F:GR €2.28 EUR +0.024

B8F Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for B8F.
View Industry Companies

Industry Analysis


Industry Average

Valuation B8F Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.7x
Price/Book 18.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOFRONTERA AG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at